Sprout shareholders reclaim $1B libido drug from Valeant

Following a lawsuit filed in November 2016 against Valeant Pharmaceuticals, female libido drug Addyi is expected to be back in the hands of former Sprout Pharmaceuticals shareholders by the end of the year.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.